March 19 Forum to Discuss Serious Illness Care Planning

February 13, 2025

The MMA will host a virtual Physician Forum on “Changing the Culture and Systems of Health Care to Improve Serious Illness Care Planning” on Wednesday, March 19 from noon to 1 pm.  

The objectives for the forum, which will be led by Erik Fromme, MD, MCR FAAHPM, lead faculty from Ariadne Labs, founded by Atul Gawande, MD, in 2012, include: 

• Describe the state of serious illness care planning in health systems 

• Summarize proposed best practices for serious illness care planning and the role of palliative care clinicians 

• Describe the tools, training approach, and systems change components of the Serious Illness Care Program (SICP) 

• Review evidence of the impact of the SICP on outcomes of patients with serious illness 

• Demonstrate serious illness conversation using the guide and debrief 
   

The world-renowned and research-based Serious Illness Care program is currently used by dozens of health systems across the country.  Fromme will be joined by Vic Sandler, MD, a geriatrician and hospice and palliative care specialist with HealthPartners, who serves on the advisory council for MMA's Center for Advancing Serious Illness Communication (CASIC).  For more information, please visit www.advancingsic.org.

The forum, which is sponsored by Copic, is free for all, but registration is required. Click here to register.    

The Minnesota Medical Association (MMA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.   

The Minnesota Medical Association designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.   

Disclosure to learners: None of the individuals in control of content for this educational activity have relevant financial relationship to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. This activity did not receive commercial support from an ineligible company.